Towards new tuberculosis drugs
The need for better drugs to treat tuberculosis has never been greater. Despite insufficient funding for discovery research, intensive efforts have been made to find and develop new lead compounds capable of reducing the duration of the present treatment known as DOTS (directly observed therapy short course), from 6 to under 4 months. This minireview describes the progress achieved during the last 5 years and highlights some of the successes without neglecting the problems.
- View record in Web of Science
Keywords: directly observed therapy short course (DOTS) ; moxifloxacin ; Pa-824 ; R207910 ; serine/threonine kinase ; Sq109 ; Multidrug-Resistant Tuberculosis ; Combinatorial Lead Optimization ; Mycobacterium-Tuberculosis ; In-Vitro ; Nitroimidazopyran Pa-824 ; Antituberculosis Agents ; Bactericidal Activity ; Murine Tuberculosis ; Atp Synthase ; Identification
Record created on 2012-07-04, modified on 2016-08-09